A possible new treatment for excessive abdominal fat associated with HIV-related lipodystrophy was presented at IAS 2008.

In a disappointing finding from the REAL study, little difference was shown in visceral fat levels from those who shifted to atazanavir/ritonavir versus those remaining on their existing boosted protease inhibitor.

This Treataware fact sheet explains the current knowledge about cardiovascular (heart) disease risk in people living with HIV/AIDS, and some strategies for minimising risk.

While newer antiretrovirals do not appear to cause lipoatrophy, the disfiguring side effect characterised by loss of fat from the face and limbs, the problem is still very much with us. David Menadue examins the latest research and treatments.

A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years.

The annual conference of the Australasian Society for HIV Medicine (ASHM) was held in Melbourne in November. This article summarises some key developments.

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports.

In September 2006, the International Association of Physicians in AIDS Care will mark a decade of highly active antiretroviral therapy. Has it really been 10 years since the so-called Protease Moment? KIRSTY MACHON reports on where we have come from – and where to from here.

A Treataware fact sheet on Lipoatrophy – the loss or ‘wasting’ of fat from the face, as well as sometimes the buttocks, upper arms legs or thighs. Options for prevention, treatment and management of fat loss associated with HIV treatments.

Are our fat tummies caused by HIV drugs, or are they just a sign we're getting older? DAVID MENADUE examines the medical debate.